Merck KGaA - EU regulator calls for review of Erbitux (cetuximab) / cancer vaccine Stimuvax (BLP25 liposome vaccine)

Safety concerns: 
1) Erbitux (cetuximab)
2) cancer vaccine Stimuvax (BLP25 liposome vaccine)

A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov

Note: actively recruiting as at March 24th, 2010
A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov